CYBN Cybin Inc.

Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.

As of 09/16/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  11/11/2020
Outstanding shares:  159,864,758
Average volume:  1,211,946
Market cap:   $353,651,232
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      40-F
Valuation   (See tab for details)
PE ratio:   -25.87
PB ratio:   4.34
PS ratio:   -2,562,690.09
Return on equity:   -55.82%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy